{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:58:55Z","timestamp":1781060335055,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00520-026-10847-z","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:33:17Z","timestamp":1780410797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretreatment neutrophil-to-lymphocyte ratio (NLR) as a potential risk marker for febrile neutropenia (FN) in breast and ovarian cancer during first-cycle chemotherapy"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8474-5749","authenticated-orcid":false,"given":"Faraz","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6244-3883","authenticated-orcid":false,"given":"Fakhra Nain","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3248-8024","authenticated-orcid":false,"given":"Azaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4067-1417","authenticated-orcid":false,"given":"Fakeeda","family":"Durrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1106-9340","authenticated-orcid":false,"given":"Noor Ul Ain","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8479-9428","authenticated-orcid":false,"given":"Imad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia Ud Din","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9967-4106","authenticated-orcid":false,"given":"Asif Riaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"10847_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3322\/caac.21727","volume":"72","author":"BE Gould Rothberg","year":"2022","unstructured":"Gould Rothberg BE, Quest TE, Yeung S-C et al (2022) Oncologic emergencies and urgencies: a comprehensive review. CA Cancer J Clin 72:570\u2013593. https:\/\/doi.org\/10.3322\/caac.21727","journal-title":"CA Cancer J Clin"},{"key":"10847_CR2","first-page":"2026","volume":"3","author":"National Comprehensive Cancer Network","year":"2025","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): hematopoietic growth factors. Version 3:2026","journal-title":"Version"},{"key":"10847_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.6004\/jnccn.2017.7010","volume":"15","author":"Y Li","year":"2017","unstructured":"Li Y, Family L, Yang S-J et al (2017) Risk of febrile neutropenia associated with select myelosuppressive chemotherapy regimens in a large community-based oncology practice. J Natl Compr Canc Netw 15:1122\u20131130. https:\/\/doi.org\/10.6004\/jnccn.2017.7010","journal-title":"J Natl Compr Canc Netw"},{"key":"10847_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist 27:625\u2013636. https:\/\/doi.org\/10.1093\/oncolo\/oyac074","journal-title":"Oncologist"},{"key":"10847_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109\u2013118. https:\/\/doi.org\/10.6004\/jnccn.2008.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"10847_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11899-013-0171-4","volume":"8","author":"MK Keng","year":"2013","unstructured":"Keng MK, Sekeres MA (2013) Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep 8:370\u2013378. https:\/\/doi.org\/10.1007\/s11899-013-0171-4","journal-title":"Curr Hematol Malig Rep"},{"key":"10847_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58111508","volume":"58","author":"OM Halalsheh","year":"2022","unstructured":"Halalsheh OM, Al Zu\u2019bi YO, Al Sharie AH et al (2022) The prognostic utility of lymphocyte-based measures and ratios in chemotherapy-induced febrile neutropenia patients following granulocyte colony-stimulating factor therapy. Medicina (Mex) 58. https:\/\/doi.org\/10.3390\/medicina58111508","journal-title":"Medicina (Mex)"},{"key":"10847_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","volume":"19","author":"W Hosmer","year":"2011","unstructured":"Hosmer W, Malin J, Wong M (2011) Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 19:333\u2013341. https:\/\/doi.org\/10.1007\/s00520-010-0821-1","journal-title":"Support Care Cancer"},{"key":"10847_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","volume":"195","author":"HM Mehta","year":"2015","unstructured":"Mehta HM, Malandra M, Corey SJ (2015) G-CSF and GM-CSF in neutropenia. J Immunol 195:1341\u20131349. https:\/\/doi.org\/10.4049\/jimmunol.1500861","journal-title":"J Immunol"},{"key":"10847_CR10","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde\u2010Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916\u20131924. https:\/\/doi.org\/10.1002\/cncr.20983","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10847_CR11","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/s0959-8049(99)00259-2","volume":"36","author":"J Chang","year":"2000","unstructured":"Chang J (2000) Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36(Suppl 1):S11-14. https:\/\/doi.org\/10.1016\/s0959-8049(99)00259-2","journal-title":"Eur J Cancer"},{"key":"10847_CR12","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1200\/JCO.1998.16.7.2392","volume":"16","author":"JH Silber","year":"1998","unstructured":"Silber JH, Fridman M, DiPaola RS et al (1998) First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 16:2392\u20132400. https:\/\/doi.org\/10.1200\/JCO.1998.16.7.2392","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10847_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007913.pub2","volume":"2012","author":"P Renner","year":"2012","unstructured":"Renner P, Milazzo S, Liu JP et al (2012) Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev (10). https:\/\/doi.org\/10.1002\/14651858.CD007913.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"10847_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427\u2013437. https:\/\/doi.org\/10.1634\/theoncologist.10-6-427","journal-title":"Oncologist"},{"key":"10847_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190\u2013199. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10847_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10549-013-2454-9","volume":"138","author":"VM Chia","year":"2013","unstructured":"Chia VM, Page JH, Rodriguez R et al (2013) Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Breast Cancer Res Treat 138:621\u2013631. https:\/\/doi.org\/10.1007\/s10549-013-2454-9","journal-title":"Breast Cancer Res Treat"},{"key":"10847_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299\u20131309. https:\/\/doi.org\/10.1007\/s00520-008-0430-4","journal-title":"Support Care Cancer"},{"key":"10847_CR18","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038\u20133051. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.3038","journal-title":"J Clin Oncol"},{"key":"10847_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdn560","volume":"20","author":"P Jenkins","year":"2009","unstructured":"Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20:34\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdn560","journal-title":"Ann Oncol"},{"key":"10847_CR20","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdr493","volume":"23","author":"P Jenkins","year":"2012","unstructured":"Jenkins P, Scaife J, Freeman S (2012) Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 23:1766\u20131771. https:\/\/doi.org\/10.1093\/annonc\/mdr493","journal-title":"Ann Oncol"},{"key":"10847_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ajh.10363","volume":"73","author":"CW Choi","year":"2003","unstructured":"Choi CW, Sung HJ, Park KH et al (2003) Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 73:263\u2013266. https:\/\/doi.org\/10.1002\/ajh.10363","journal-title":"Am J Hematol"},{"key":"10847_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","volume":"88","author":"I Ray-Coquard","year":"2003","unstructured":"Ray-Coquard I, Borg C, Bachelot T et al (2003) Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 88:181\u2013186. https:\/\/doi.org\/10.1038\/sj.bjc.6600724","journal-title":"Br J Cancer"},{"key":"10847_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00000421-199902000-00025","volume":"22","author":"M Kondo","year":"1999","unstructured":"Kondo M, Oshita F, Kato Y et al (1999) Early monocytopenia after chemotherapy as a risk factor for neutropenia. Am J Clin Oncol 22:103\u2013105. https:\/\/doi.org\/10.1097\/00000421-199902000-00025","journal-title":"Am J Clin Oncol"},{"key":"10847_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/TCRM.S318370","volume":"17","author":"O Alshari","year":"2021","unstructured":"Alshari O, Al Zu\u2019bi YO, Al Sharie AH et al (2021) Evaluating the prognostic role of monocytopenia in chemotherapy-induced febrile neutropenia patients treated with granulocyte colony-stimulating factor. Ther Clin Risk Manag 17:963\u2013973. https:\/\/doi.org\/10.2147\/TCRM.S318370","journal-title":"Ther Clin Risk Manag"},{"key":"10847_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096413","volume":"9","author":"K Chen","year":"2014","unstructured":"Chen K, Zhang X, Deng H et al (2014) Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study. PLoS One 9. https:\/\/doi.org\/10.1371\/journal.pone.0096413","journal-title":"PLoS One"},{"key":"10847_CR26","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917\u20131927. https:\/\/doi.org\/10.1002\/cncr.25691","journal-title":"Cancer"},{"key":"10847_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/annonc\/mdn655","volume":"20","author":"M Moreau","year":"2009","unstructured":"Moreau M, Klastersky J, Schwarzbold A et al (2009) A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 20:513\u2013519. https:\/\/doi.org\/10.1093\/annonc\/mdn655","journal-title":"Ann Oncol"},{"key":"10847_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-6","volume":"10","author":"RS Phillips","year":"2012","unstructured":"Phillips RS, Wade R, Lehrnbecher T et al (2012) Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 10. https:\/\/doi.org\/10.1186\/1741-7015-10-6","journal-title":"BMC Med"},{"key":"10847_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"J Natl Cancer Inst"},{"key":"10847_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11060-018-2914-5","volume":"139","author":"M Chowdhary","year":"2018","unstructured":"Chowdhary M, Switchenko JM, Press RH et al (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689\u2013697. https:\/\/doi.org\/10.1007\/s11060-018-2914-5","journal-title":"J Neurooncol"},{"key":"10847_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111906","volume":"9","author":"X Zhang","year":"2014","unstructured":"Zhang X, Zhang W, Feng L (2014) Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis. PLoS ONE 9. https:\/\/doi.org\/10.1371\/journal.pone.0111906","journal-title":"PLoS ONE"},{"key":"10847_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJK Guthrie","year":"2013","unstructured":"Guthrie GJK, Charles KA, Roxburgh CSD et al (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88:218\u2013230. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10847_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0794-1","volume":"19","author":"J-L Ethier","year":"2017","unstructured":"Ethier J-L, Desautels D, Templeton A et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19. https:\/\/doi.org\/10.1186\/s13058-016-0794-1","journal-title":"Breast Cancer Res"},{"key":"10847_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s12282-020-01096-x","volume":"27","author":"J Dan","year":"2020","unstructured":"Dan J, Tan J, Huang J et al (2020) The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer 27:982\u2013988. https:\/\/doi.org\/10.1007\/s12282-020-01096-x","journal-title":"Breast Cancer"},{"key":"10847_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.clnu.2020.05.005","volume":"40","author":"TC Borges","year":"2021","unstructured":"Borges TC, Gomes TL, Pichard C et al (2021) High neutrophil to lymphocytes ratio is associated with sarcopenia risk in hospitalized cancer patients. Clin Nutr 40:202\u2013206. https:\/\/doi.org\/10.1016\/j.clnu.2020.05.005","journal-title":"Clin Nutr"},{"key":"10847_CR36","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.21873\/invivo.12970","volume":"36","author":"S Kumazawa","year":"2022","unstructured":"Kumazawa S, Mizuno T, Muramatsu N et al (2022) Neutrophil-lymphocyte ratio is associated with occurrence of febrile neutropenia in patients treated with 5-Fluorouracil and Cisplatin. In Vivo 36:2379\u20132383. https:\/\/doi.org\/10.21873\/invivo.12970","journal-title":"In Vivo"},{"key":"10847_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.31557\/apjcb.2020.5.3.81-87","volume":"5","author":"C Chantharakhit","year":"2020","unstructured":"Chantharakhit C, Sujaritvanichpong N (2020) Pretreatment absolute neutrophil-to-lymphocyte ratio (NLR) predict the risk for febrile neutropenia in the first cycle adjuvant chemotherapy for breast cancer. Asian Pac J Cancer Biol 5:81\u201387. https:\/\/doi.org\/10.31557\/apjcb.2020.5.3.81-87","journal-title":"Asian Pac J Cancer Biol"},{"key":"10847_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"10847_CR39","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.pan.2016.09.007","volume":"16","author":"H Cheng","year":"2016","unstructured":"Cheng H, Luo G, Lu Y et al (2016) The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology 16:1080\u20131084. https:\/\/doi.org\/10.1016\/j.pan.2016.09.007","journal-title":"Pancreatology"},{"key":"10847_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104568","volume":"83","author":"O Badran","year":"2025","unstructured":"Badran O, Darawshe A, Sharif S et al (2025) Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+\/HER-2 breast cancer patients treated with CDK4\/6 inhibitors. Breast 83. https:\/\/doi.org\/10.1016\/j.breast.2025.104568","journal-title":"Breast"},{"key":"10847_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.862257","volume":"13","author":"BH Segal","year":"2022","unstructured":"Segal BH, Fridlender Z (2022) Editorial: neutrophils in cancer. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.862257","journal-title":"Front Immunol"},{"key":"10847_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12929-015-0194-3","volume":"22","author":"AV Belikov","year":"2015","unstructured":"Belikov AV, Schraven B, Simeoni L (2015) T cells and reactive oxygen species. J Biomed Sci 22:85. https:\/\/doi.org\/10.1186\/s12929-015-0194-3","journal-title":"J Biomed Sci"},{"key":"10847_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08845-1","volume":"23","author":"ZC El\u00e7io\u011flu","year":"2023","unstructured":"El\u00e7io\u011flu ZC, Errington L, Metes B et al (2023) Pooled prevalence of lymphopenia in all-cause hospitalisations and association with infection: a systematic review and meta-analysis. BMC Infect Dis 23. https:\/\/doi.org\/10.1186\/s12879-023-08845-1","journal-title":"BMC Infect Dis"},{"key":"10847_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56218-z","volume":"9","author":"R Howard","year":"2019","unstructured":"Howard R, Kanetsky PA, Egan KM (2019) Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep 9. https:\/\/doi.org\/10.1038\/s41598-019-56218-z","journal-title":"Sci Rep"},{"key":"10847_CR45","first-page":"341","volume":"56","author":"S Shakinah","year":"2024","unstructured":"Shakinah S, Nelwan EJ, Lubis AM et al (2024) Comparison of CISNE and MASCC score in predicting complications on post chemotherapy febrile neutropenia. Acta Medica Indones 56:341\u2013348","journal-title":"Acta Medica Indones"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10847-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10847-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10847-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:28:49Z","timestamp":1781058529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10847-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10847"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10847-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9106686\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Review Board\/Ethics Committee (IRB\/EC Approval No. INMOL-53-216). This study was performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for participation was obtained from all participants before inclusion in the study.Written informed consent for participation was obtained from all participants before inclusion in\u00a0the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from all participants before inclusion in the study for the\u00a0publication of data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"600"}}